Home
Questo sito è destinato ai professionisti sanitari.

Modulo 3 del Navigator sulla fibrosi polmonare: Decisioni terapeutiche in condizioni di incertezza

Condividi

Descrizione

Questa attività è sostenuta da una sovvenzione formativa indipendente concessa da BMS. Questo programma formativo online è stato ideato per gli operatori sanitari di tutto il mondo, ad eccezione del Regno Unito.

Unitevi all’esperto Corey Kershaw, MD, per una sessione approfondita su come gestire la terapia antifibrotica e sui meccanismi emergenti. Questa sessione esplora le strategie per mitigare in modo proattivo gli eventi avversi gastrointestinali, preservare l’aderenza alla terapia e integrare le nuove evidenze nei piani terapeutici personalizzati per ciascun paziente.

Questo è il terzo modulo su quattro. I moduli uno, due e quattro sono disponibili qui.

Punti salienti della sessione

  • Gestire in modo proattivo gli effetti collaterali gastrointestinali attraverso strategie antiemetiche, adeguamenti dietetici e riduzioni della dose previste dal foglietto illustrativo prima di interrompere la terapia antifibrotica.
  • Utilizzare strumenti di monitoraggio domiciliare e punteggi relativi agli esiti riferiti dai pazienti per monitorare le tendenze di aderenza e individuare precocemente i rischi di tollerabilità.
  • Valutare il panorama terapeutico in espansione, compresi gli inibitori della PDE4B di recente approvazione e gli agenti sperimentali emergenti in fase 3 (agonisti della prostaciclina e antagonisti dell’LPA1).
  • Implementare sistemi di supporto alle decisioni cliniche che combinino la verifica dell’idoneità con promemoria di monitoraggio attivo per guidare gli aggiustamenti terapeutici.

Destinatari

Questa attività è rivolta a pneumologi, reumatologi, radiologi toracici, patologi, infermieri specializzati in pneumologia e assistenti medici/collaboratori che svolgono un ruolo centrale nella diagnosi e nella gestione della fibrosi polmonare idiopatica (IPF) e della fibrosi polmonare post-polmonite (PPF). È inoltre pensata per medici di base, terapisti respiratori, farmacisti e altri professionisti sanitari multidisciplinari coinvolti nella cura dei pazienti affetti da fibrosi polmonare.

Docenti

Il dott. Corey Kershaw è professore presso il Dipartimento di Medicina Interna, all’interno della Divisione di Medicina Polmonare e Terapia Intensiva dell’UT Southwestern. Ricopre il ruolo di responsabile dei servizi clinici della Divisione di Medicina Polmonare e Terapia Intensiva, nonché quello di direttore medico dell’Unità di Terapia Intensiva Medica e della Terapia Respiratoria presso il William P. Clements Jr. University Hospital. Vanta una vasta esperienza clinica nella gestione di patologie polmonari complesse e nella medicina di terapia intensiva.

Informativa

In conformità con le linee guida EBAC®, tutti i relatori e i moderatori che partecipano a questo programma hanno dichiarato o segnalato eventuali conflitti di interesse che potrebbero influenzare le loro presentazioni. Il Comitato Organizzatore/Direttore del corso ha la responsabilità di garantire che tutti i potenziali conflitti di interesse rilevanti per l’evento siano comunicati al pubblico prima dell’inizio delle attività di formazione continua.

Il dott. Corey Kershaw, docente di questa attività, ha dichiarato di aver intrattenuto rapporti finanziari negli ultimi 36 mesi con le seguenti aziende non ammissibili: consulente, advisor e relatore per Boehringer Ingelheim; ricercatore per Avalyn Pharma, Bristol Myers Squibb, Daewoong Pharmaceutical, PureTech Health/Celea Therapeutics e United Therapeutics.

Il personale di MedAll, così come i responsabili della pianificazione e i revisori, non hanno rapporti finanziari rilevanti da dichiarare con aziende non ammissibili.

Informazioni sull’EBAC® CME:

Questa attività è stata pianificata e realizzata in conformità con i requisiti e le politiche di accreditamento dell’European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

MedAll è un fornitore accreditato dall’EBAC dal 2025. Il Consiglio europeo per l’accreditamento della formazione continua per i professionisti sanitari (EBAC) accredita i programmi di formazione continua (CE) per la comunità medica internazionale.

Questo programma è accreditato dal Consiglio europeo per l’accreditamento della formazione continua per i professionisti sanitari (EBAC®) per 15 minuti di tempo di formazione effettivo.

In conformità con le linee guida dell’EBAC, tutti i relatori/moderatori che partecipano a questo programma hanno dichiarato o segnalato potenziali conflitti di interesse che potrebbero causare una parzialità nelle presentazioni. Il Comitato Organizzatore/Direttore del corso ha la responsabilità di garantire che tutti i potenziali conflitti di interesse rilevanti per l’evento siano dichiarati al pubblico prima dell’inizio delle attività di formazione continua.

L’EBAC® ha stipulato un accordo di riconoscimento reciproco dell’equivalenza sostanziale rispettivamente con l’Accreditation Council for CME (ACCME) degli Stati Uniti e con il Royal College of Physicians and Surgeons of Canada.

Grazie a un accordo tra l’European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) e l’American Medical Association, i medici possono convertire i crediti ECM esterni EBAC® in crediti AMA PRA di Categoria 1. Le informazioni sulla procedura per convertire i crediti EBAC® in crediti AMA sono disponibili sul sito web dell’AMA. Altri professionisti sanitari possono ottenere dall’AMA un certificato di partecipazione a un’attività idonea alla conversione dei crediti in crediti AMA PRA di Categoria 1.

L’Accreditation Council for Continuing Medical Education (ACCME) e il Royal College of Physicians and Surgeons of Canada hanno stipulato un accordo di equivalenza sostanziale dei sistemi di accreditamento con l’EBAC.

L’EBAC® è membro dell’Accademia Internazionale per l’Accreditamento della Formazione Professionale Continua (IACPDA) e membro partner dell’Associazione Internazionale delle Autorità di Regolamentazione Medica (IAMRA).

Come ottenere i crediti ECM EBAC®:

Per ottenere i crediti ECM e ricevere il certificato, si prega di partecipare all’attività e di completare la valutazione finale. Dopo aver completato la valutazione, riceverete un link al vostro certificato.

Costi di partecipazione

La partecipazione a questo programma è gratuita.

Questa attività di formazione continua è attiva a partire dal 1° novembre 2026 e scadrà il 30 settembre 2027.

Tempo stimato per il completamento di questa attività: 15 minuti

Obiettivi formativi

Al termine di questa attività, i partecipanti saranno in grado di:

  • Integrare la stratificazione del rischio, l’imaging ad alta risoluzione e la valutazione multidisciplinare per differenziare e diagnosticare precocemente e con precisione la fibrosi polmonare idiopatica (IPF) e la fibrosi polmonare post-polmonite (PPF) rispetto ad altre malattie polmonari interstiziali (ILD).
  • Attuare strategie diagnostiche e gestionali multidisciplinari per migliorare il riconoscimento tempestivo, l’invio a specialisti e l’assistenza coordinata per i pazienti affetti da fibrosi polmonare (PF).
  • Applicare le conoscenze relative ai meccanismi d’azione e alle evidenze cliniche alle decisioni terapeutiche, compresa la selezione dei pazienti e la tempistica della terapia.

Community simili

Visualizza tutto

Eventi e video on-demand simili

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

All right. Um, we're gonna move on to treatment decision under uncertainty. So we're still, um, taking care of Margaret. Margaret has now started ninitinib, and we're seeing her back, you know, uh, to talk about how she's doing with ninitinib. Look at her home spirometry at week 8. And um her home dashboard, we're gonna look at. She's, um, things are going well with her lungs, maybe not so well with other things lung adjacent, so we'll discuss that. So, week 8 on nintentinib, her home spirometry looks great. It's unchanged. That's our primary goal when we start a patient on an antifibrotic like nintentinib. However, she's having some difficulty with um some side effects. She reports nausea on most days. Um, she's missed two doses in the last week because of the side effect, and she reports a 1.5 kg weight loss since initiation after eight weeks, and I would argue that that's, that's significant, um, after only eight weeks. So we're now, we're now detecting an adherence risk. So our dashboard's advising us that perhaps we should, um, review the dose and talk to the patient. And really this is not an uncommon scenario and I, I think one of the ways to mitigate this that we've discussed is, you know, getting ahead of the side effects at least from a knowledge-based perspective because it's really the GI intolerance that leads to um discontinuation or underdosing because of dose changes of the antifibrotics and patients sometimes won't tell you this, so it's important that that this becomes Um, every patient touch point, you ask them these questions, not just how they're feeling in terms of their pulmonary symptoms, but how they're tolerating the medication because they may not bring it up. There may be an embarrassment factor, um, you know, patients want our approval and they're perhaps uncomfortable sharing that, you know, they're taking their, their doses, not every day. So, um, here's our home monitoring tab with our dashboard. Um, we identified that, uh, our patient Margaret is taking nintentinib 150 mg twice per day. She's reporting moderate GI side effects and she's missed two doses in the last week and there's our weight change. So this, this home monitoring dashboard really concept really gives us A nice snapshot of what's going on with our patient at this moment. We can see her side effects summary. We're already getting an alert that the patient is stopping in spite of apparent drug effectiveness, and again, Underdosing or discontinuation of the antifibrotics is, is really true in the real world, so we have to discuss these questions. But the nice thing about the dashboard concept is that we can monitor the patient and perhaps pick up these issues early so the patient's therapy is not only optimized but side effects are mitigated to improve adherence. So, Here's an informal poll, just hands up in the chat, um, you know, who has had a patient out there stop an anti-fibrotic because of GI GI side effects without telling you. Um, so choice A, yes, and we found out late. Choice B, yes, but we caught it early. C, not that I know of. D, I don't prescribe these antifibrotics, or E, I prefer not to say. Let's give everyone an opportunity to answer with raising your hands. OK. Very interesting results there. I think we all feel very similarly about this. All right, let's move on. So, how can we address this problem? We've spent time during our presentation with you discussing Uh, how to identify the patient problems, how to start them on therapy, but we really need to address tolerability, you know, our, our job is not done once we decide to treat a patient with an antifibrotic. So let's talk about some of the GI side effects of these antifibrotics. The first thing that we need to do is support the patient. If they're having nausea, consider an anti-emetic. If, um, are they taking the, the medicines with food? Nintendonib is so important to take with food. Um, if you really try to take it on an empty stomach, you're going to have GI side effects. So we need to review that with the patient, not just at the time of, uh, prescription, but at each subsequent visit to assess if there are any diet issues, either they're having trouble getting a full meal in Or they perhaps noticed some associations. They're having a full meal, but when they eat certain foods, the side effect is worse. Uh, could there be another medication that's a factor here, um, that's contributing to the nausea, so don't necessarily decide it's the intentative, for example, that's the problem. It could be something else. If we've tried the support route first and the patient is still having difficulty, that's the time to consider dose reduction. Nintentinib has a both 150 and 100 mg doses. Um, this is supported by the labeling that you can decrease the dose for side effects, um, to 100 mg twice per day. Um, this at least preserves, preserves the patients taking treatment and post-hoc data suggests that there is a benefit to taking the lower dose. I'm asked this question a lot at um presentations that I give. Uh, patients ask me this question, why not start the patient at the lower dose to mitigate the side effects and we really wanna optimize the dosing, optimize the benefit. The 100 mg dose really should be reserved for side effects mitigation, not, um, in order to get them to talk the dose upfront because the reality is most patients do just fine on the full dose. So you don't wanna necessarily undertreat the patient. Out of fear of side effects before you've even tried. Um, so I, I certainly urge everyone if you're gonna start someone on, on nintentinib, use the top dosing, 150 mg twice per day and reserve the lower dose if the patient's having side effects and your, um, non-pharmacological mitigation efforts such as nausea medications, addressing food, um, issues, co-medications. Try that first before looking at a dose reduction. If the patient still has trouble, then you can consider dosing, pausing, uh, the, the nice thing about these medicines, at least in my experience is the patient's struggling, if you give them a break on the medicine, the side effect generally goes away. So, you know, having a structured interruption, name the date you're gonna stop. We're going to stop for 1 week, we're gonna stop for 2 weeks and then I want you to start again. So don't just leave it open-ended because as I said, The side effects really are dosing dependent. If you stop the medication today, very likely you will not have side effects tomorrow. So, don't leave it open-ended because we, again, we wanna optimize time on drug to maximize benefit. Perhaps after the pause and rechallenge the patient is still having trouble, then you could consider um adding, uh, either adding a new medication or switching to something else. So, for example, prophenidone is an option, but remember, in, at least in the United States and the European Union, Um, prophenidone is indicated only for IPF. So our patient has rheumatoid arthritis, so it would be an off-label use to, uh, for prophenidone and RAILD. This is not part of routine care, at least in the United States that I can speak of. You, you run into some reimbursement issues for the patients when you're using things off-label, so it requires some navigation with insurances and co-pays. Um, there are certainly ways to do it, but it's not always straightforward. And whatever you decide to do with the patient, you really need to close the loop, you know, if someone needs to call her and talk to her about this because that's, you know, yes, the dashboard concept is helpful because we can pick up things early, but we need to let the patient know that we're watching. We care, we know what's going on, and these are the things we want to try. Um. Don't make the switch before, you know, rescuing the adherence. That's a really key principle here. So if we give up on antifibrotics, we, we've helped nobody for this. So we really want to do everything we can on the current medicine before we make a switch, OK? So, tolerability tolerability management, that really is treatment also. We're rescuing adherence, we're documenting what we do and then we're gonna call the patient, closing the loop. So what else could we do? So here's some emerging um Medications for treatment of these diseases. We'll start with neuronommalast. That's the newest kid on the block. This is an oral medication. It is a PDE4B inhibitor approved uh throughout the world, um, both for IPF and for non-IPF progressive pulmonary fibrosis. So we've got two indications for this. The way, um, neuronommalast works is we have to think about what PDE4B does. PDE4B. Um, is, um, what that does is degrades cyclic AMP. In cyclic AMP we wanna think of as a fibroblast break. So we, we need cyclic AMP to cool off the activation that occurs when fibroblasts are recruited following lung injury, OK? So anything we can do to enhance cyclic AMP in this environment is helpful to mitigate the fibrosing process. By blocking PDE4B, we increase cyclic AMP. In the, uh, in the epithelial environment here which will cool off activation after fibroblast recruitment. So by preserving cyclic AMP will dampen the inflammatory cytokine release and decrease fibroblast activation. So two mechanisms. This was shown.